Ontology highlight
ABSTRACT:
SUBMITTER: Zhang Z
PROVIDER: S-EPMC3408577 | biostudies-literature | 2012 Jul
REPOSITORIES: biostudies-literature
Zhang Zhenfeng Z Lee Jae Cheol JC Lin Luping L Olivas Victor V Au Valerie V LaFramboise Thomas T Abdel-Rahman Mohamed M Wang Xiaoqi X Levine Alan D AD Rho Jin Kyung JK Choi Yun Jung YJ Choi Chang-Min CM Kim Sang-We SW Jang Se Jin SJ Park Young Soo YS Kim Woo Sung WS Lee Dae Ho DH Lee Jung-Shin JS Miller Vincent A VA Arcila Maria M Ladanyi Marc M Moonsamy Philicia P Sawyers Charles C Boggon Titus J TJ Ma Patrick C PC Costa Carlota C Taron Miquel M Rosell Rafael R Halmos Balazs B Bivona Trever G TG
Nature genetics 20120701 8
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors. Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo ...[more]